267 related articles for article (PubMed ID: 23396258)
1. Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization.
Su Z; Shi Y; Xiao Y; Sun M; Ping Q; Zong L; Li S; Niu J; Huang A; You W; Chen Y; Chen X; Fei J; Tian J
Int J Pharm; 2013 Apr; 447(1-2):281-92. PubMed ID: 23396258
[TBL] [Abstract][Full Text] [Related]
2. Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine.
Su Z; Niu J; Xiao Y; Ping Q; Sun M; Huang A; You W; Sang X; Yuan D
Mol Pharm; 2011 Oct; 8(5):1641-51. PubMed ID: 21770405
[TBL] [Abstract][Full Text] [Related]
3. Octreotide-mediated tumor cell uptake and intracellular pH-responsive drug delivery of the self-assembly supramolecular nanocarrier.
Niu J; Huang A; Xiao Y; Su Z; Li H; Ping Q; Bao X; Li S; Chen Y; Sun M
J Drug Target; 2013 May; 21(5):415-26. PubMed ID: 23597028
[TBL] [Abstract][Full Text] [Related]
4. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
[TBL] [Abstract][Full Text] [Related]
5. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin.
Hong M; Zhu S; Jiang Y; Tang G; Pei Y
J Control Release; 2009 Jan; 133(2):96-102. PubMed ID: 18840485
[TBL] [Abstract][Full Text] [Related]
6. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles.
Hong M; Zhu S; Jiang Y; Tang G; Sun C; Fang C; Shi B; Pei Y
J Control Release; 2010 Jan; 141(1):22-9. PubMed ID: 19735683
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles.
Huo M; Zou A; Yao C; Zhang Y; Zhou J; Wang J; Zhu Q; Li J; Zhang Q
Biomaterials; 2012 Sep; 33(27):6393-407. PubMed ID: 22704599
[TBL] [Abstract][Full Text] [Related]
8. Octreotide-conjugated PAMAM for targeted delivery to somatostatin receptors over-expressed tumor cells.
Peng J; Qi X; Chen Y; Ma N; Zhang Z; Xing J; Zhu X; Li Z; Wu Z
J Drug Target; 2014 Jun; 22(5):428-38. PubMed ID: 24437350
[TBL] [Abstract][Full Text] [Related]
9. Preparation of isoliquiritigenin-loaded nanostructured lipid carrier and the in vivo evaluation in tumor-bearing mice.
Zhang XY; Qiao H; Ni JM; Shi YB; Qiang Y
Eur J Pharm Sci; 2013 Jun; 49(3):411-22. PubMed ID: 23624327
[TBL] [Abstract][Full Text] [Related]
10. [Preparation of PEG-modified nanostructured lipid carriers loaded with hydroxycamptothecin and tissue distribution in mice].
Zhang XX; Gan Y; Yang XG; Zhu CL; Gan L; Nie SF; Pan WS
Yao Xue Xue Bao; 2008 Jan; 43(1):91-6. PubMed ID: 18357740
[TBL] [Abstract][Full Text] [Related]
11. Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying.
Zhang X; Pan W; Gan L; Zhu C; Gan Y; Nie S
Chem Pharm Bull (Tokyo); 2008 Dec; 56(12):1645-50. PubMed ID: 19043233
[TBL] [Abstract][Full Text] [Related]
12. Effect of alkyl chain on cellular uptake and antitumor activity of hydroxycamptothecin nanoparticles based on amphiphilic linear molecules.
Guo Y; Wang T; Zhao S; Qiu H; Han M; Dong Z; Wang X
Eur J Pharm Sci; 2018 Nov; 124():266-272. PubMed ID: 30189259
[TBL] [Abstract][Full Text] [Related]
13. Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivo.
Li H; Yuan D; Sun M; Ping Q
Drug Deliv; 2016 Nov; 23(9):3562-3572. PubMed ID: 27432585
[TBL] [Abstract][Full Text] [Related]
14. Octreotide-modified and pH-triggering polymeric micelles loaded with doxorubicin for tumor targeting delivery.
Niu J; Su Z; Xiao Y; Huang A; Li H; Bao X; Li S; Chen Y; Sun M; Ping Q
Eur J Pharm Sci; 2012 Jan; 45(1-2):216-26. PubMed ID: 22119655
[TBL] [Abstract][Full Text] [Related]
15. Formulation design and evaluation of quantum dot-loaded nanostructured lipid carriers for integrating bioimaging and anticancer therapy.
Hsu SH; Wen CJ; Al-Suwayeh SA; Huang YJ; Fang JY
Nanomedicine (Lond); 2013 Aug; 8(8):1253-69. PubMed ID: 23384703
[TBL] [Abstract][Full Text] [Related]
16. Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent Tamibarotene: characterization and evaluation.
Liu X; Zhang Z; Jiang Y; Hu Y; Wang Z; Liu J; Feng R; Zhang J; Huang G
Drug Deliv; 2015 Feb; 22(2):223-9. PubMed ID: 24559497
[TBL] [Abstract][Full Text] [Related]
17. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel.
Liu D; Liu Z; Wang L; Zhang C; Zhang N
Colloids Surf B Biointerfaces; 2011 Jul; 85(2):262-9. PubMed ID: 21435845
[TBL] [Abstract][Full Text] [Related]
18. In vivo real-time fluorescence visualization and brain-targeting mechanisms of lipid nanocarriers with different fatty ester:oil ratios.
Wen CJ; Yen TC; Al-Suwayeh SA; Chang HW; Fang JY
Nanomedicine (Lond); 2011 Nov; 6(9):1545-59. PubMed ID: 22077462
[TBL] [Abstract][Full Text] [Related]
19. Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part II. In vivo biodistribution, pharmacodynamic and hematological toxicity studies.
Negi LM; Talegaonkar S; Jaggi M; Verma AK; Verma R; Dobhal S; Kumar V
Colloids Surf B Biointerfaces; 2014 Nov; 123():610-5. PubMed ID: 25454755
[TBL] [Abstract][Full Text] [Related]
20. PEGylated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: an efficient carrier with enhanced anti-tumour effects against lung cancer.
Zhang X; Gan Y; Gan L; Nie S; Pan W
J Pharm Pharmacol; 2008 Aug; 60(8):1077-87. PubMed ID: 18644200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
